Introduction {#sec1}
============

Voltage-gated ion channels (VGICs) control electrical signaling in the brain, heart, and nervous system.^[@ref1]^ Many members of this protein superfamily are multiprotein complexes comprising both transmembrane pore-forming subunits and cytoplasmic regulatory subunits.^[@ref2]^ VGIC cytoplasmic subunits can exert strong control over channel function by conferring distinct biophysical properties to the resulting channel complex and by affecting channel biogenesis and plasma membrane trafficking.^[@ref1],[@ref3]−[@ref5]^ Although the importance of such subunits for VGIC function is well established, with the exception of a few cases,^[@ref6]−[@ref9]^ their potential as targets for the development of agents that could control channel function has been largely overlooked.^[@ref10]−[@ref12]^ Protein--protein interaction antagonists have been shown to be effective modulators of diverse protein classes^[@ref13]−[@ref17]^ but have not yet been developed and validated for any ion channel system. Hence, we asked whether we could advance this type of reagent against the exemplar VGIC high-affinity protein--protein interaction formed between the voltage-gated calcium channel pore-forming Ca~V~α~1~ and cytoplasmic Ca~V~β subunits for which there is a wealth of structural information to guide design.^[@ref18]^

High-voltage Ca~V~s (Ca~V~1s and Ca~V~2s) are the principal agents of calcium influx in excitable cells, are vital components of the machinery that regulates muscle contraction, vascular tone, hormone and neurotransmitter release, and synaptic function, and provide a prototypical example of the pivotal role of cytoplasmic subunits in VGIC function.^[@ref1],[@ref19]−[@ref21]^ Ca~V~1s and Ca~V~2s are made from at least four main components:^[@ref18],[@ref22],[@ref23]^ a Ca~V~α~1~ pore forming subunit, a cytoplasmic Ca~V~β subunit,^[@ref20],[@ref21]^ the extracellular Ca~V~α~2~δ subunit,^[@ref24]^ and a calcium sensor protein, such as calmodulin.^[@ref25]^ The Ca~V~α~1~:Ca~V~β interaction is central to the formation of properly functioning native Ca~V~s,^[@ref20],[@ref21]^ controls Ca~V~ trafficking to the plasma membrane,^[@ref3],[@ref26]−[@ref30]^ and affects a number of Ca~V~ biophysical properties including voltage-dependent activation and the rate of channel inactivation.^[@ref20],[@ref21],[@ref31]−[@ref39]^ Ca~V~α~1~ and Ca~V~β associate through a high affinity (*K*~d~ approximately nanomolar)^[@ref40]−[@ref45]^ interaction between a short peptide segment on the Ca~V~ intracellular I--II loop, known as the α-interaction domain (AID), and a groove in Ca~V~β termed the α-binding pocket (ABP).^[@ref20],[@ref46]−[@ref49]^

Ca~V~s are validated targets for drugs treating cardiovascular diseases, epilepsy, and chronic pain.^[@ref19],[@ref50]^ Well-studied modifiers of Ca~V~ function such as small molecule drugs and peptide toxins largely target the pore-forming subunit.^[@ref19],[@ref50]−[@ref52]^ Because of the central role of the AID:ABP protein--protein interaction in Ca~V~ function, there has been an interest in establishing whether interfering with this interaction might provide an alternative strategy for Ca~V~ modulation.^[@ref45],[@ref53]^ Previous studies suggesting that the Ca~V~α~1~:Ca~V~β interaction is labile^[@ref54]−[@ref57]^ and studies showing that blocking Ca~V~β action is a productive means to affect Ca~V~ function^[@ref8],[@ref9]^ support such an approach.

Because, stapled-peptide strategies have been particularly effective at targeting protein--protein interactions in which one partner is single α-helix,^[@ref17],[@ref58]^ such as in the AID:ABP case, we pursued the stapled-peptide strategy to develop AID-based inhibitors of the AID:ABP interaction and Ca~V~ function. Previously, we and others demonstrated that chemical cross-linking of *i* and *i* + 4 cysteines could be useful for α-helical peptide stabilization.^[@ref59],[@ref60]^ Here, we expand this cysteine cross-linking strategy to constrain an N-terminal capping motif^[@ref61],[@ref62]^ appended to the AID. Our studies demonstrate that stapling AID peptides with a *meta*-xylyl bridge^[@ref59],[@ref63]^ between two engineered cysteines creates AID peptides having enhanced helical content that bind Ca~V~β in a native-like manner. We find that the macrocyclic constrained cap acts as an effective means to enhance helix content and that, importantly, the enhanced AID peptide is a potent inhibitor of Ca~V~ currents that causes Ca~V~β isoform-specific inhibition of the AID:ABP interaction.

Results {#sec2}
=======

AID Backbone Modifications Increase α-Helical Content of AID {#sec2.1}
------------------------------------------------------------

Structural studies have shown that there is essentially no conformational change between the apo- and AID-bound Ca~V~β ABP.^[@ref46]−[@ref48]^ By contrast, the Ca~V~ AID peptide undergoes a large conformational change between an unbound disordered state and the Ca~V~β-bound helical conformation.^[@ref45],[@ref47],[@ref64],[@ref65]^ This binding event involves a substantial entropic penalty, approximately −14 cal mol^--1^ K^--1^,^[@ref45]^ that due to the essentially unchanged structure of the ABP must arise from the entropic cost of ordering the AID. In order to overcome this problem, we pursued a chemical stabilization strategy to enhance the helical structure of the AID unbound state ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}A).

![Backbone staples increase AID helical content. (A) Schematic showing the conformational ensemble of the native AID (top) versus the desired effect of incorporating the *m*-xylyl backbone staple. (B) AID, AID-CAP, and AID-CEN peptide sequences. The capping box residues are highlighted in red. Underline denotes *m*-xylyl linker cross-linking positions. (C) Circular dichroism spectra of AID (black), AID-CAP (blue), and AID-CEN (orange) at 70 μM and 4 °C.](cn-2016-004543_0001){#fig1}

Previously, we and others demonstrated that introduction of *m*-xylyl linker between two cysteines (*i*, *i* + 4) by thiol alkylation^[@ref63]^ could be used to stabilize the α-helical conformation in peptides.^[@ref59],[@ref60]^ This cysteine alkylation strategy has the advantage of not requiring unnatural amino acids. To date, all strategies for stapled peptide synthesis have focused on introduction of linkers along one α-helix face, an approach that can buttress the structure but that does not restrain the α-helix polar ends. To address this issue, we introduced an N-terminal capping motif^[@ref61],[@ref62]^ into two AID peptides, AID-CAP and AID-CEN ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). This capping motif includes an N~Cap~ position serine intended to stabilize the structure through hydrogen bonds to the exposed amide protons at the helix N-terminus, an N~1~ position proline to act as a helix initiator, and an N~3~ position glutamate placed to contribute hydrogen bonds to the N~Cap~ serine and amide backbone ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). In the case of AID-CAP, two cysteines were included to make a macrocyclic capping box sequence, Cys-Ser-Pro-Leu-Glu-Cys, in which the cysteine residues should allow facile macrocyclization with *m*-xylyl bromide ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). AID-CEN bears an unconstrained capping motif and a more conventional (*i*, *i* + 4) cross-linking motif within the helix (K435C and D439C) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}B). In both peptides, cysteine positions for staple attachment were chosen to reside on the exposed AID surface based on structures of the Ca~V~β--AID complexes in order to avoid introducing interfering interactions.

Circular dichroism (CD) studies of AID-CAP and AID-CEN indicated that *m*-xylyl staple incorporation affected the secondary structure to different extents depending on the staple location ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C). The *m*-xylyl staple in AID-CEN caused a modest change that reduced the intensity of the signal at 208 nm relative to the unmodified AID. By contrast, AID-CAP displayed the hallmark double minima associated with α-helical structure that was absent in the unmodified AID peptide^[@ref66]^ and that indicates that the N-terminal cap site is a potent element for stabilizing the AID helical conformation.

X-ray Crystal Structures Show That Ca~V~β~2a~:Stapled AID Complexes Are Similar to Native Complexes {#sec2.2}
---------------------------------------------------------------------------------------------------

To investigate the structural integrity of the backbone staple designs, we crystallized and determined the structure of AID-CAP and AID-CEN bound to a unimolecular Ca~V~β~2a~ construct previously used for extensive Ca~V~β~2a~:AID thermodynamic binding studies.^[@ref45]^ Crystals of the AID-CAP complex grew in the *H*3 space group having one molecule in the asymmetric unit and diffracted X-rays to 1.9 Å ([Table S1](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)). Structure solution by molecular replacement (*R*/*R*~free~= 18.5/23.0%) revealed a Ca~V~β~2a~:AID structure similar to that determined previously for the unconstrained AID^[@ref48]^ (RMSD~Cα~ = 1.2 Å) ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A) except for a few minor differences. The Ca~V~β~2a~ α1 helix is longer by ten residues ([Figure S1A](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)), and there is a moderate divergence in the angle of the α2 helix. This element precedes the disordered V2/HOOK domain and extends from the SH3 domain far from the AID binding site ([Figure S1A](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)) and is affected by crystal lattice contacts. Excluding the α2 helix from the comparison, the structures of the Ca~V~β~2a~:AID- and Ca~V~β~2a~:AID-CAP complexes are essentially identical (RMSD~Cα~= 0.55 Å over residues 43--127, 217--273, 295--414).

![Crystal structures of Ca~V~β~2a~:stapled peptide complexes. (A) Structure of the Ca~V~β~2a~:AID-CAP complex. Ca~V~β~2a~ (cyan) is shown in surface rendering. AID-CAP (deep teal) is shown as a cartoon having side chains shown as sticks. Locations of the AID-CAP and ABP, nucleotide kinase (NK) and SH3 domains of Ca~V~β~2a~ are indicated. (B) 2*F*~o~ -- *F*~c~ electron density (1.0σ) for the AID-CAP *m*-xylyl staple. Select AID-CAP residues are indicated. (C) Structure of the Ca~V~β~2a~:AID-CEN complex. Ca~V~β~2a~ (yellow orange) is shown in surface rendering. AID-CEN (orange) is shown as a cartoon having side chains shown as sticks. Locations of the AID-CEN and ABP, nucleotide kinase (NK), and SH3 domains of Ca~V~β~2a~ are indicated. (D) 2*F*~o~ -- *F*~c~ electron density (1.0σ) for the AID-CEN *m*-xylyl staple. Select AID-CAP residues are indicated.](cn-2016-004543_0002){#fig2}

The structure of the Ca~V~β~2a~:AID-CAP complex ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A) reveals that the AID-CAP peptide binds to the α-binding pocket (ABP) in a manner that is identical to the wild-type AID ([Figure S1A](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)) using the main hydrophobic anchors Tyr437, Trp440, and Ile441 and interactions with two buried water molecules coordinated by the side chain of Ty437 ([Figure S1B](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)).^[@ref45]−[@ref48]^ The *m*-xylyl linker connecting the *i* → *i* + 5 cysteines was clearly visible in the electron density ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B). This moiety makes no interactions with Ca~V~β, indicating that its effects are only on the AID conformational properties as intended. The N-terminal AID-CAP residue, Cys427, adopts a nonhelical conformation that occupies the β-backbone conformation portion of the Ramachandran plot. Subsequent residues form a regular α-helix. Within the *m*-xylyl stabilized region, the Glu431 side chain contacts the backbone nitrogen of Ser428, satisfying the backbone requirement for this otherwise free functional group and the intention of the sequence design. The cysteine members of the *m*-xylyl staple, Cys427 and Cys432, have side chain χ1 angles of (+60°) and *meta* (−180°), respectively, resulting in a 5.9 Å distance between the Cys427 and Cys432 sulfurs that allows for unstrained connection through the *meta*-xylene functional group.

We also obtained crystals of the Ca~V~β~2a~:AID-CEN complex that grew in the *P*2~1~2~1~2~1~ spacegroup, diffracted X-rays to 1.8 Å, and the structure was solved by molecular replacement (*R*/*R*~free~ = 15.8/19.6%) ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C, [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)). In this structure, Ca~V~β~2a~ has an extended C-tail (residues 417--425) ([Figure S1A](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)), but otherwise, the Ca~V~β~2a~ component is essentially unchanged from the Ca~V~β~2a~ core^[@ref48]^ (RMSD~Cα~ = 0.4 Å over residues 43--127, 217--273, 295--414) or Ca~V~β~2a~ in the Ca~V~β~2a~:AID-CAP complex ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}C, RMSD~Cα~ = 0.4 Å over residues 43--127, 217--273, 295--414). As with the Ca~V~β~2a~:AID-CAP complex, the AID-CEN backbone forms a regular α-helix and the Ca~V~β~2a~:AID-CEN interaction is unaltered from the native structure ([Figure S1B](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)). Density for the *i* → *i* + 4 *m*-xylyl backbone staple was well resolved ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}D) and shows that, similar to the situation with AID-CAP, the *m*-xylyl staple plays no direct role in in Ca~V~β binding. The cysteine anchors for the *m*-xylyl staple, Cys435 and Cys439, have side chain χ1 angles of −180° and −161°, respectively. This conformation leads to a 6.5 Å distance between the Cys435 and Cys439 sulfurs. The ∼20° deviation from the regular low energy conformers of Cys439 suggests that there is a small energetic cost for liganding the anchor atoms at a 6.5 Å distance. Comparison of the N-terminal capping motifs in the Ca~V~β~2a~:AID-CAP and Ca~V~β~2a~:AID-CEN complexes shows that the designed hydrogen bond network among the N~Cap~, N~2~, N~3~, and N~4~ positions is well formed in the presence of the AID-CAP *m*-xylyl staple ([Figure S1C](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)). This network is also present in the unconstrained capping motif in AID-CEN but has longer hydrogen bonds and slightly different interactions for Glu431 ([Figure S1D](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)). Together, the structural data demonstrate that the *m*-xylyl staple is compatible with the helical conformation of the AID and in the case of AID-CAP helps to organize the N-terminal capping motif.

AID Helix Staples Lower the Entropic Cost of Ligand Binding {#sec2.3}
-----------------------------------------------------------

Having determined that the backbone staples are able to affect AID helix content ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}) and are structurally compatible with the Ca~V~β-AID interaction ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}), we used isothermal titration calorimetry (ITC) to investigate whether the AID staples impacted binding thermodynamics. Experiments measuring Ca~V~1.2 AID binding to the Ca~V~β~2a~ core yielded an affinity in good agreement with prior measurements *K*~d~ = 6.6 ± 2.0 nM vs 5.3 nM^[@ref45]^ ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}A, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). This binding reaction is driven by a favorable enthalpic component (Δ*H* = −15.6 ± 2.4 kcal mol^--1^) that is opposed by a large entropic cost (Δ*S* = −16.7 ± 6.0 cal mol^--1^ K^--1^) that most likely results from the requirement to reduce the degrees of freedom of the highly disordered ligand upon binding.

![Backbone modifications decrease entropic cost of Ca~V~β~2a~ binding. Exemplar ITC titrations for (A) 20 μM AID into 2 μM Ca~V~β~2a~, (B) 20 μM AID-CEN into 2 μM Ca~V~β~2a~ core, and (C) 20 μM AID-CAP-peptide into 2 μM Ca~V~β~2a~.](cn-2016-004543_0003){#fig3}

###### AID Peptide:Ca~V~β~2a~ Thermodynamic Binding Parameters

  AID peptide   *n*   *K*~d~ (nM)   *N*           Δ*H* (kcal mol^--1^)   Δ*S* (cal mol^--1^ K^--1^)   *K*~d~/*K*~d~ Ca~V~1.2 AID
  ------------- ----- ------------- ------------- ---------------------- ---------------------------- ----------------------------
  Cav1.2 AID    3     6.6 ± 2.0     0.94 ± 0.07   --15.6 ± 2.4           --16.7 ± 6.0                 1
  AID-CEN       2     5.2 ± 1.5     1.05 ± 0.03   --10.2 ± 0.1           2.2 ± 0.5                    0.79 ± 0.33
  AID-CAP       3     5.1 ± 1.6     1.02 ± 0.10   --12.3 ± 1.4           --4.6 ± 4.1                  0.77 ± 0.34

ITC measurements with AID-CEN and AID-CAP revealed that both peptides bind Ca~V~β~2a~ with affinities similar to wild-type AID, 5.2 ± 1.5 and 5.1 ± 1.6 nM, respectively ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}B,C, [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) but that incorporation of the *m*-xylyl moiety affects the thermodynamic binding parameters of the Ca~V~β~2a~:AID interaction. Consistent with the incorporation of the *m*-xylyl staple and decrease in random coil as seen by CD ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}), the entropic cost of complex formation was reduced relative to the wild-type for both stapled peptides (Δ*S* = 2.2 ± 0.5 and −4.6 ± 4.1 cal mol^--1^ K^--1^ for AID-CEN and AID-CAP, respectively). However, this reduction of the unfavorable entropic component was offset by a binding enthalpy reduction (Δ*H* = −10.2 ± 0.1 and −12.3 ± 1.4 kcal mol^--1^, AID-CEN and AID-CAP, respectively). Because neither *m*-xylyl staple contributes to the AID:ABP interaction and there are no obvious changes in ABP interaction site contacts ([Figure S1A,B](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)), this result appears to be an example of enthalpy--entropy compensation^[@ref67]^ and may originate in the loss of some of the favorable enthalpy of helix formation^[@ref68]^ due to the preordering of the helical structure in the unbound state. Even though the effects of enthalpy--entropy compensation left the binding affinity unaffected, the data demonstrate that the inclusion of the staple was effective at reducing the disorder of the unbound AID as designed.

Stapled AID Peptides Compete with Mutant but Not Wild-type Ca~V~1.2:Ca~V~β~2a~ Complexes {#sec2.4}
----------------------------------------------------------------------------------------

Because AID-CAP and AID-CEN had similar affinities for Ca~V~β but the AID-CAP had the highest amount of helical structure, we focused on testing whether AID-CAP could affect Ca~V~ function. Ca~V~β binding to the pore-forming Ca~V~α~1~ subunit AID is known to cause clear changes to channel gating properties, such as the extent and speed of inactivation and the channel activation potential (*V*~1/2~).^[@ref20],[@ref45],[@ref64]^ We were concerned that the tight interaction between Ca~V~α~1~ and Ca~V~β subunits might be difficult to compete with an exogenous peptide, particularly because the Ca~V~1.2:Ca~V~β~2a~ interaction has been shown to be long-lived unless it is weakened by ABP--AID interface mutations.^[@ref69]^ Hence, we first performed competition experiments using a Ca~V~α~1~ subunit bearing an AID mutation that lowers the Ca~V~β affinity by ∼1000-fold (Y437A, *K*~d~ = 5.3 vs 5263 nM for wild-type and Y437A, respectively^[@ref45]^). To test the ability of AID peptides to interfere with Ca~V~ function, we measured the response of preassembled, functional, plasma membrane Ca~V~ complexes expressed in *Xenopus* oocytes to competitor peptides ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}), similar to the approach we used previously to uncover the direct competition between calcium sensor proteins on Ca~V~s.^[@ref70]^ Two principal inactivation processes govern Ca~V~ function, voltage-dependent inactivation (VDI)^[@ref71],[@ref72]^ and calcium-dependent inactivation (CDI).^[@ref25],[@ref72],[@ref73]^ Because VDI is essentially absent with Ca~V~β~2a~^[@ref20]^ and CDI requires Ca~V~β,^[@ref64]^ we measured CDI over the course of 30 min postinjection to monitor functional consequences of AID peptide injection on Ca~V~β~2a~ containing channels ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

![Schematic of AID peptide competition experiment. *Xenopus* oocytes expressing Ca~V~ channels (complexes of Ca~V~1.2 (black lines), Ca~V~β (purple), Ca~V~α~2~δ (gray lines), and CaM (red) (left) are injected with AID-CAP peptide at *t* = 0 and initial channel properties are recorded using two-electrode voltage clamp). Panels show two possible outcomes. Resistant complexes have no changes in channel biophysical properties (orange vs black lines). Labile channel complexes in which the AID competitor peptide can capture released Ca~V~β leaving an unoccupied I--II loop (purple) show biophysical changes. For simplicity, changes in channel current amplitude, an additional possible outcome for labile complexes, is not depicted.](cn-2016-004543_0004){#fig4}

One functional signature of the interaction of Ca~V~1.2 with Ca~V~β~2a~ is the extent and speed of inactivation, which are more complete and faster, respectively, in the presence of Ca~V~β~2a~ ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Prior to peptide injection, Ca~V~1.2-Y437A:Ca~V~β~2a~ channels were essentially functionally identical to wild-type Ca~V~1.2:Ca~V~β~2a~ channels ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Within 30 min of injection of 400 μM AID or AID-CAP peptides, we observed substantial and similar changes from both peptides with respect to the extent of channel inactivation 300 ms after activation (*t*~i300~) (*t*~i300~ decreased from 64.9% ± 1.9% to 44.8% ± 2.1% and 65.5% ± 1.3% to 43.1% ± 3.7% for AID and AID-CAP, respectively) ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A--C). In fact, at 30 min after peptide injection, the extent of inactivation was indistinguishable from Ca~V~1.2 expressed in the absence of Ca~V~β (*t*~i300~ = 47.9% ± 1.2%, 44.8% ± 2.1% and 43.1% ± 3.7% for no Ca~V~β, AID (30 min), and AID-CAP (30 min), respectively), suggesting that the peptides had interfered completely with Ca~V~β binding. By contrast, injection of an AID mutant peptide in which the three most important residues for binding to Ca~V~β were mutated to alanine (Y437A/W440A/I441A, termed "HotA"^[@ref45]^) showed no specific effects on fractional inactivation and had effects indistinguishable from water injection ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}) (*t*~i300~ decreased from 68.8% ± 1.0% to 63.7% ± 1.3% and 67.2% ± 1.9% to 59.8% ± 2.6% for HotA and water, respectively, [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} and [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). In addition to the *t*~i300~ changes, the fraction of the fast inactivation component decreased after injection of either AID or AID-CAP to levels similar to Ca~V~1.2 expressed without a Ca~V~β subunit ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C).

![AID-CAP affects Ca~V~1.2Y437A:Ca~V~β~2a~ channels. (A) Exemplar normalized *I*~Ca~ traces at a test potential of +20 mV for *Xenopu*s oocytes expressing Ca~V~1.2-Y437A:Ca~V~β~2a~ channels recorded after injection of water, 400 μM HotA, 400 μM AID-CAP, or 400 μM AID at the indicated postinjection times. Gray curves at times 10, 15, 20, 25, and 30 min show initial 5 min response. (B) Fractional inactivation after 300 ms (*t*~i300~) and (C) *A*~1~, the relative amplitude of the fast inactivation component, for Ca~V~1.2-Y437A:Ca~V~β~2a~ currents as a function of postinjection time for water (inverted black triangles), 400 μM HotA (red squares), 400 μM AID (maroon triangles), or 400 μM AID-CAP (blue circles). (D) Change in half maximal activation potential (Δ*V*~1/2~) between recordings at 5 and 30 min postinjection. (E) *I*~max~(*t*)/*I*~max~(5 min) and (F) *I*~max~(*t*)/*I*~max~(5 min) normalized to *I*~max~(*t*)/*I*~max~(5 min) of HotA injection as a function of postinjection time. Symbols are as in panels B and C. Lines in panel F show fit to *I*(*t*) = *A* exp (−*t*/τ) + *C* (exponential) or *I*(*t*) = *mt* + *C* (linear), where *I* is the recorded current, *A* is the amplitude of the loss of current (for exponential fit), *m* is the slope factor (linear fit), and *C* is the residual current after 30 min. Results for AID and AID-CAP are statistically different from HotA in all panels (*P* \< 0.001). AID and AID-CAP results are not statistically different from each other except in panels E and F where *P* \< 0.001.](cn-2016-004543_0005){#fig5}

###### Ca~V~1.2 Inactivation Parameters and GV Relationship[a](#t2fn1){ref-type="table-fn"}

                                                    *t*~i300~ (%)   *A*~1~ (%)     τ~1~ (ms)      *A*~2~ (%)        τ~2~ (ms)         *I*~max~          *V*~1/2~    *N*
  --------------------------- --------------------- --------------- -------------- -------------- ----------------- ----------------- ----------------- ----------- -----
                              Ca~V~1.2:Ca~V~β~2a~   68.4 ± 1.1      49.4 ± 1.9     25.4 ± 1.2     21.3 ± 1.2        159.6 ± 8.4       --0.411 ± 0.054   8.1 ± 1.2   25
  Ca~V~1.2-Y437A:Ca~V~β~2a~   66.0 ± 3.2            51.6 ± 3.7      31.2 ± 4.6     22.5 ± 3.9     177.3 ± 10.9      --0.816 ± 0.237   7.5 ± 1.4         6           
  Ca~V~1.2:Ca~V~β~3~          75.9 ± 1.1            70.3 ± 0.9      59.8 ± 2.5                                      --0.964 ± 0.008   5.5 ± 1.4         20          
                                                    *59.9 ± 1.9*    *33.9 ± 3.0*   *25.4 ± 1.6*   *312.0 ± 47.7*                                                    
  Ca~V~1.2, no Ca~V~β         47.9 ± 1.2            26.8 ± 3.6      75.5 ± 10.3    48.4 ± 4.8     348.3 ± 41.4      --0.245 ± 0.028   18.1 ± 1.0        14          
  Ca~V~1.2-Y437A:Ca~V~β~2a~   water 5 min           67.2 ± 1.9      51.9 ± 2.2     28.0 ± 1.5     19.7 ± 1.2        170.5 ± 6.3       --0.722 ± 0.092   7.8 ± 1.3   5
  water 30 min                59.8 ± 2.6            42.6 ± 2.6      31.6 ± 2.9     23.7 ± 1.6     200.5 ± 13.8      --0.430 ± 0.075   11.1 ± 1.2        5           
  HotA, 5 min                 68.8 ± 1.0            54.0 ± 1.2      33.2 ± 1.4     20.0 ± 1.3     212.5 ± 16.4      --1.001 ± 0.153   4.7 ± 1.4         18          
  HotA, 30 min                63.7 ± 1.3            47.2 ± 1.2      34.5 ± 1.7     22.0 ± 1.0     197.9 ± 10.1      --0.578 ± 0.064   7.1 ± 1.1         18          
  AID-CAP, 5 min              65.5 ± 1.3            52.7 ± 1.3      32.9 ± 1.7     18.8 ± 1.1     212.6 ± 18.6      --1.016 ± 0.122   5.4 ± 1.4         16          
  AID-CAP, 30 min             43.1 ± 3.7            24.8 ± 3.2      52.8 ± 8.2     38.2 ± 3.0     469.8 ± 160.1     --0.156 ± 0.022   16.9 ± 1.0        15          
  AID, 5 min                  64.9 ± 1.9            48.5 ± 1.8      35.0 ± 1.5     24.1 ± 1.6     251.5 ± 16.1      --0.883 ± 0.111   2.9 ± 1.7         10          
  AID, 30 min                 44.8 ± 2.1            24.5 ± 3.0      53.3 ± 14.4    31.0 ± 1.9     304.0 ± 50.9      --0.242 ± 0.021   15.1 ± 2.0        10          
  Ca~V~1.2:Ca~V~β~2a~         water 5 min           60.8 ± 1.0      40.0 ± 1.1     34.6 ± 3.9     27.1 ± 0.8        222.8 ± 31.6      --1.344 ± 0.248   9.1 ± 1.8   5
  water 30 min                58.1 ± 1.4            38.3 ± 2.5      37.3 ± 3.0     27.1 ± 2.0     227.3 ± 12.1      --0.785 ± 0.074   11.6 ± 0.7        5           
  HotA, 5 min                 66.8 ± 0.3            47.5 ± 1.0      28.4 ± 0.7     24.6 ± 1.0     185.7 ± 2.1       --0.734 ± 0.110   10.5 ± 1.5        3           
  HotA, 30 min                62.1 ± 0.2            44.4 ± 0.8      33.5 ± 2.3     24.7 ± 0.6     209.5 ± 13.2      --0.531 ± 0.098   9.0 ± 0.5         3           
  AID-CAP 400 μM, 5 min       63.7 ± 1.9            41.6 ± 2.5      33.0 ± 2.3     28.9 ± 1.8     215.8 ± 13.2      --0.966 ± 0.154   9.2 ± 1.5         8           
  AID-CAP 400 μM, 30 min      57.1 ± 1.6            33.1 ± 2.0      35.0 ± 1.7     28.6 ± 2.0     209.7 ± 9.3       --0.555 ± 0.132   13.0 ± 1.7        8           
  AID-CAP 2.8 mM, 5 min       64.6 ± 1.3            52.4 ± 3.1      29.2 ± 3.3     19.3 ± 2.2     172.5 ± 23.4      --0.984 ± 0.142   7.2 ± 0.7         5           
  AID-CAP 2.8 mM, 30 min      62.4 ± 2.6            48.1 ± 5.5      30.7 ± 6.0     27.3 ± 1.3     172.2 ± 25.9      --0.465 ± 0.079   10.4 ± 0.7        5           
  Ca~V~1.2:Ca~V~β~3~          HotA, 5 min           79.2 ± 2.2      79.7 ± 2.3     63.0 ± 2.4                                         --0.932 ± 0.041   6.7 ± 2.9   5
                                                    *61.0 ± 2.4*    *38.5 ± 1.5*   *27.9 ± 0.8*   *256.8 ± 10.8*                                        *5*         
  HotA, 30 min                77.0 ± 2.9            78.0 ± 2.7      71.4 ± 4.6                                      --0.577 ± 0.069   8.6 ± 3.3         5           
                                                    *56.5 ± 2.0*    *42.9 ± 4.4*   *30.0 ± 1.4*   *241.1 ± 14.6*                                        *5*         
  AID-CAP, 5 min              73.2 ± 1.4            75.9 ± 1.2      76.2 ± 4.2                                      --0.889 ± 0.135   6.3 ± 1.6         6           
                                                    *57.8 ± 1.2*    *48.0 ± 3.7*   *42.0 ± 8.3*   *639.1 ± 238.3*                                       *6*         
  AID-CAP, 30 min             48.3 ± 4.1            66.3 ± 5.0      188.7 ± 30.2                                    --0.081 ± 0.023   20.5 ± 2.8        6           
                                                    *ND*            *ND*           *ND*           *ND*                                                              
  AID, 5 min                  73.4 ± 2.0            76.9 ± 3.1      62.6 ± 7.6                                      --0.860 ± 0.096   10.4 ± 2.2        7           
                                                    *54.0 ± 2.7*    *40.0 ± 5.2*   *34.1 ± 1.4*   *354.4 ± 119.2*                                       *7*         
  AID, 30 min                 49.8 ± 1.9            65.0 ± 4.0      118.2 ± 11.0                                    --0.116 ± 0.010   21.0 ± 2.0        7           
                                                    *ND*            *ND*           *ND*           *ND*                                                              

Data are expressed as mean values ± SEM; τ values were determined at a holding potential of +20 mV (see [Materials and Methods](#sec4){ref-type="other"}); *t*~i300~ denotes percent inactivation at 300 ms. *I*~max~ is the maximal current amplitude. *V*~1/2~ values for Ca~V~1.2 and mutants were determined with calcium as the charge carrier. Data were fit using the equation *I* = *G*~max~(*V*m -- *V*~rev~)/(1 + exp\[(*V*~1/2~ -- *V*~m~)/*K*~a~\]), where *I* is the measured peak current at each *V*~m~, *G*~max~ is the maximal macroscopic conductance, *V*~m~ is the test potential, *V*~rev~ is the reversal potential, *V*~1/2~ is the midpoint of activation, and *K*~a~ is the slope factor.^[@ref29]^ ND, value not determined. Italic lines highlight double exponential fit values for Ca~V~β~3~ experiments.

A second functional signature of the interaction of Ca~V~β~2a~ with Ca~V~1.2 is a hyperpolarizing shift of ∼10 mV in the channel activation (*V*~1/2~ = 18.1 ± 1.0 and 8.1 ± 1.2 mV for Ca~V~1.2 without and with Ca~V~β~2a~, respectively, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). In Ca~V~1.2 Y437A:Ca~V~β~2a~ channels, competition with both the AID and AID-CAP peptides reduced this effect of Ca~V~β on channel activation (*V*~1/2~ = 15.1 ± 2.0 and 16.9 ± 1.0 mV for AID and AID-CAP, respectively) ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). By contrast, oocytes coexpressing Ca~V~1.2-Y437A:Ca~V~β~2a~ that were injected with either water or the HotA peptide did not show any changes in gating characteristics. These observations are consistent with the notion that AID and AID-CAP peptide injection counteracted the effect of Ca~V~β~2a~ on the voltage-dependency of channel activation and suggest that the observed effects arise from disruption of the Ca~V~1.2:Ca~V~β~2a~ interaction.

Recordings from Ca~V~1.2-Y437A:Ca~V~β~2a~ expressing oocytes challenged by AID or AID-CAP also showed consistently higher rundown, compared to recordings from water or HotA peptide injected oocytes ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}E and [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). This increased rundown may reflect some enhanced internalization of channel once the Ca~V~1.2:Ca~V~β interaction is lost or possible inhibition of the formation of new complexes. Subtraction of the water-injected baseline revealed that the AID and AID-CAP induced rundown of *I*~max~ reached steady state on the time scale of minutes ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}F) and that the AID-CAP peptide was more potent than the unstapled wild-type. The rundown process could be well fit by a single exponential ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}F) (τ = 5.3 ± 0.9 and 4.1 ± 0.4 min for AID and AID-CAP, respectively). All of the observed characteristic changes caused by AID and AID-CAP injection are consistent with a disruption of the Ca~V~1.2:Ca~V~β~2a~ interaction.

Given that the AID-CAP peptide performed better than the AID, we next asked whether AID-CAP could compete with Ca~V~β~2a~ bound to an unaltered channel. Contrasting the results with Ca~V~1.2-Y437A, the effects of 400 μM AID-CAP injection into wild-type Ca~V~1.2 expressing oocytes were not different from the effects seen with water or similar concentration injections of HotA on Ca~V~1.2-Y437A:Ca~V~β~2a~. Increasing the injected AID-CAP concentration to 2.8 mM did not cause functional effects that were different from the negative controls with the exception of inducing a slight increase in channel rundown ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). Thus, unlike the situation in which the AID:ABP interaction is weakened by the Y437A mutation in the Ca~V~1.2 α~1~-subunit AID, native Ca~V~1.2:Ca~V~β~2a~ complexes appear to be sufficiently stable to resist kinetic competition by the injected peptides.

![Ca~V~1.2:Ca~V~β~2a~ channels resist AID-CAP modulation. (A) Exemplar normalized *I*~Ca~ traces at a test potential of +20 mV for *Xenopu*s oocytes expressing Ca~V~1.2:Ca~V~β~2a~ channels recorded after injection of water, 400 μM HotA, 400 μM AID-CAP, or 2.8 mM AID-CAP at the indicated postinjection times. Gray curves at times 10, 15, 20, 25, and 30 min show initial 5 min response. (B, C) Postinjection values of (B) fractional inactivation after 300 ms (*t*~i300~) and (C) *A*~1~, the relative amplitude of the fast inactivation component, for Ca~V~1.2-Y437A:Ca~V~β~2a~ currents as a function of postinjection time for water (inverted black triangles), 400 μM HotA (red squares), 400 μM AID-CAP (blue circles), or 2.8 mM AID-CAP (teal triangles). (D) Change in half maximal activation potential (Δ*V*~1/2~) between recordings 5 and 30 min postinjection. (E) *I*~max~(*t*)/*I*~max~(5 min) and (F) *I*~max~(*t*)/*I*~max~(5 min) normalized to HotA injection as a function of postinjection time. Symbols are as in panel B and C. Lines in panel F show fit to *I*(*t*) = *A* exp(−*t*/τ) + *C* (exponential) or *I*(*t*) = *mt* + *C* (linear), where *I* is the recorded current, *A* is the amplitude of the loss of current (for exponential fit), *m* is the slope factor (linear fit), and *C* is the residual current after 30 min. There are no statistically significant differences in the results shown in the panels, except for panels E and F where the AID-CAP 2.8 mM results are statistically significant from Hot A (*P* = 0.034).](cn-2016-004543_0006){#fig6}

Stapled AID Peptides Compete with Functional Ca~V~1.2/Ca~V~β~3~ Complexes in Oocytes {#sec2.5}
------------------------------------------------------------------------------------

Ca~V~β~2a~ bears an N-terminal palmitoylation site^[@ref74]^ that anchors it to the plasma membrane making it different from other Ca~V~β isoforms. This membrane tethering should increase the effective concentration^[@ref75]^ of the AID:ABP interaction and could thwart the ability of AID peptides to compete with the native AID:ABP interaction. To test this idea, we examined whether AID and AID-CAP peptides could affect wild-type Ca~V~1.2 coexpressed with nonpalmitoylated isoform Ca~V~β~3~ that shares a conserved structure and ABP-AID interface with Ca~V~β~2a~.^[@ref45],[@ref46]^ By strong contrast with the Ca~V~1.2:Ca~V~β~2a~ results ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}), injection of AID or AID-CAP into oocytes expressing Ca~V~1.2:Ca~V~β~3~ channels at the maximal peptide concentration that was ineffective against Ca~V~1.2:Ca~V~β~2a~ channels (2.8 mM, [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}) resulted in a striking change of the channel properties compared to the control HotA peptide ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}A, [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Over the course of 30 min, competition with AID and AID-CAP decreased the extent of inactivation (*t*~i300~ from 73.4% ± 2.0% to 49.8% ± 1.9% and from 73.2% ± 1.5% to 48.3% ± 4.1%, respectively, [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}B), prolonged τ of inactivation ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}C), and shifted the activation *V*~1/2~ (from 6.3 ± 1.6 to 20.5 ± 2.8 mV and from 10.4 ± 2.2 to 21.0 ± 2.0 mV for AID-CAP and AID, in contrast to HotA, from 6.7 ± 2.9 to 8.6 ± 3.3 mV [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}D). Following injection with both the AID-CAP and AID peptides, there was also a clear change in channel inactivation kinetics, which changed from one having two components to a monoexponential process. Similar to the Ca~V~1.2-Y437A:Ca~V~β~2a~ experiments, injection of AID and AID-CAP peptides resulted in strongly increased current rundown, consistent with a loss of active channels on the plasma membrane ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}E). All of these functional changes are consistent with the near complete disruption of the Ca~V~1.2α~1~:Ca~V~β~3~ interaction and are absent in currents from oocytes expressing Ca~V~1.2:Ca~V~β~3~ challenged with the HotA peptide. The similar performance of the AID and AID-CAP peptides matches their comparable affinities for Ca~V~β ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} and [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). There is a slight advantage for the AID-CAP version that suggests that the peptide staple improves the performance of the peptide in a cellular setting ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}).

![AID-CAP affects Ca~V~1.2:Ca~V~β~3~ channels. (A) Exemplar normalized *I*~Ca~ traces at a test potential of +20 mV for *Xenopu*s oocytes expressing Ca~V~1.2:Ca~V~β~3~ channels recorded after injection of 4 mM HotA, 2.8 mM AID-CAP, or 2.8 mM AID at the indicated postinjection times. Gray curves at times 10, 15, 20, 25, and 30 min show initial 5 min response. (B, C) Postinjection values of (B) fractional inactivation after 300 ms (*t*~i300~) and (C) *t*, the fast inactivation time constant of Ca~V~1.2:Ca~V~β~3~ currents, as a function of postinjection time for 4 mM HotA (red squares), 2.8 mM AID (maroon triangles), or 2.8 mM AID-CAP (blue circles). (D) Change in half maximal activation potential (Δ*V*~1/2~) between recordings 5 and 30 min postinjection. (E) *I*~max~(*t*)/*I*~max~(5 min) and (F) *I*~max~(*t*)/*I*~max~(5 min) normalized to HotA injection as a function of postinjection time. Symbols are as in panels B and C. Lines in panel F show fit to *I*(*t*) = *A* exp(−*t*/τ) + *C* (exponential) or *I*(*t*) = *mt* + *C* (linear), where *I* is the recorded current, *A* is the amplitude of the loss of current (for exponential fit), *m* is the slope factor (linear fit), and *C* is the residual current after 30 min. Because of the switch in inactivation behavior, to facilitate comparisons, values from monoxponential fits of the channel kinetics were used for panel C. Results for AID and AID-CAP are statistically different from HotA in all panels (*P* \< 0.001 for panels B, E, and F; *P* \< 0.05 for panels C and D). AID and AID-CAP results are not statistically different from each other except in panels C, E, and F where *P* \< 0.001.](cn-2016-004543_0007){#fig7}

Measurement of the time constant for the loss of channels by fitting to a single exponential yields τ = 5.3 ± 0.7 and 4.6 ± 0.4 min for AID-CAP and AID, respectively. These values are notably similar to those measured for Ca~V~1.2 Y437A:Ca~V~β~2a~ complexes (5.3 ± 0.9 and 4.1 ± 0.4 min, respectively, [Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}F) and are within a factor of 3 of the reported *k*~off~ for dissociation of purified Ca~V~2.2 I--II loop peptide and Ca~V~β~2b~ (τ = 2.1 min).^[@ref44]^ These observations, together with the similar binding properties of all AID and Ca~V~β isoforms,^[@ref45]^ suggest that the functional effects we observe are driven by dissociation of Ca~V~β from the channel. Taken together, our data demonstrate that it is possible to use exogenous AID peptides to disrupt Ca~V~α:Ca~V~β interactions. Differences in the labile nature of the AID:Ca~V~β interaction lead to Ca~V~β isoform-specific effects even though the target AID:ABP interactions are strictly conserved.

Discussion {#sec3}
==========

The function, regulation, and biogenesis of many VGIC superfamily members rely on the formation of protein--protein complexes between VGIC pore-forming and cytoplasmic subunits.^[@ref1],[@ref76]^ Well-studied examples of how this class of protein--protein interactions can affect VGIC biophysical properties and cellular targeting have been elaborated for Ca~V~1 and Ca~V~2 pore-forming subunits with Ca~V~β^[@ref20],[@ref23],[@ref45]−[@ref48]^ and the interaction of Kv1 and Kv4 voltage gated potassium channels with either Kvβ^[@ref4],[@ref77]^ or KChIPs,^[@ref4],[@ref78]^ respectively. In particular, application of Ca~V~1 AID peptides to channel containing membrane patches has been reported to modulate Ca~V~1.2 channels in a manner consistent with competition of the Ca~V~α~1~:Ca~V~β interaction^[@ref55]^ and comprehensive structural and functional studies have shown that cortisone can modulate Kv1 channels by competing with the K~V~1--Kvβ interaction.^[@ref6],[@ref7]^ These initial studies suggest that antagonists of the protein--protein interactions between pore-forming and cytoplasmic VGIC components may offer an alternative strategy to control channel function that contrasts the classical approaches that target the pore-forming subunit.^[@ref19],[@ref50]−[@ref52],[@ref79]^

Targeting protein--protein interactions remains challenging.^[@ref14],[@ref16]^ Nevertheless, notable successes have been made in developing protein--protein interaction antagonists for a variety of cellular targets such as Bcl-X~L~, p53, and estrogen receptors.^[@ref14]−[@ref17]^ Despite the many successes with intracellular targets, there has been little successful development reported regarding VGIC protein--protein interaction antagonists. Two studies have detailed the search for compounds that would affect Ca~V~α--Ca~V~β^[@ref53]^ and Kv4--KChIP interactions,^[@ref80]^ but neither validated the reported compounds as authentic protein--protein interaction antagonists. Given such lack of progress targeting ion channel protein--protein interactions as a point of pharmacological intervention and questions about the degree to which interactions between pore-forming and cytoplasmic subunits may be labile, there has been reasonable skepticism about whether targeting such interactions can be a viable strategy to control channel function in cellular settings.^[@ref12],[@ref19]^ Our studies here, using a classic paradigm for cytoplasmic subunit modulation, that of the Ca~V~α~1~:Ca~V~β interaction, now validate the concept of using protein--protein antagonists to control a VGIC and should open a path to further development of this type of strategy to control channel function.

Protein--protein interactions involving the binding of an α-helix to a partner protein represent one of the most attractive architectures for protein--protein interaction antagonist development^[@ref15]^ as the interaction surface is limited and there are a variety of strategies for improving the properties of the α-helical partner. The AID:ABP interaction presents an example of this sort of interaction in an ion channel complex. The α-helical element of the complex, the AID, lacks structure in its unbound state^[@ref45],[@ref47],[@ref64],[@ref65]^ and binds to a well-defined Ca~V~β cleft, the ABP, that undergoes minimal conformational change.^[@ref46]−[@ref48]^ Because α-helix stabilization strategies have proven successful for targeting many protein--protein interactions mediated by a similar general architecture^[@ref15]^ and the binding energy of the AID:ABP is focused into a hotspot in the center of the AID helix,^[@ref45]^ we reasoned that pursuing a stapled peptide strategy^[@ref58]^ to enhance the stability of the AID helix might provide a first step in the development of Ca~V~β-directed inhibitors of Ca~V~ function.

Incorporation of an *m*-xylyl staple, a strategy used previously to stabilize the protease inhibitor calpastatin^[@ref59]^ and β-catenin,^[@ref60]^ enhanced AID helix formation when placed at either N-terminal (AID-CAP) or central (AID-CEN) positions ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}C). The AID-CAP configuration proved superior for inducing helical content. We attribute this effect to the stabilization of an engineered helix cap by the *m*-xylyl staple ([Figure S1C](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf)) and the importance of helix nucleation.^[@ref81],[@ref82]^ Our crystallographic studies show that neither *m*-xylyl staple position altered the way the AID peptides bind Ca~V~β ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). As anticipated, *m*-xylyl staple incorporation reduced the entropic penalty of Ca~V~β binding ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) in a manner consistent with reduction of disorder in the unbound AID. Nevertheless, despite this effect, lack of interference of the staples with Ca~V~β complex formation, and lack of conformational change in the Ca~V~β ABP, there was a concomitant reduction in the large enthalpic gain of complex formation that resulted in no measurable change in Ca~V~β binding affinity between the unconstrained and stapled AIDs ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Such entropy--enthalpy compensation effects are not uncommon in protein--ligand recognition and design efforts.^[@ref67]^ In the case of the stapled AIDs, the ordering of the helical conformation may have traded away some of the gain in favorable enthalpy associated with the formation of helical backbone interactions^[@ref68]^ that would otherwise be associated with the binding reaction. The structural information obtained here should enable strategies using other cross-linking sites or the combination of multiple staples to provide a path toward more efficacious peptide-based Ca~V~α:Ca~V~β protein--protein interaction inhibitors. Notably, even in the absence of affinity enhancement effects, the helical staples may offer advantages, as our cell-based assays indicated that the stapled peptide outperformed the unstapled AID ([Figures [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"}). Hence, there may be multiple layers of benefit to helix stabilization in a cellular context that go beyond the effects on binding affinity.

Two challenges to targeting the AID:ABP interaction are competition with a nanomolar native interaction^[@ref45]^ and the fact that the AID:ABP interface comprises well-conserved interactions among the isoforms of both partners.^[@ref45]^ Despite these challenges, our functional studies showed that injection of either wild-type AID or AID-CAP into *Xenopus* oocytes expressing Ca~V~1.2-Y437A:Ca~V~β~2a~ or Ca~V~1.2:Ca~V~β~3~ channel complexes resulted in biophysical changes that were consistent with loss of Ca~V~β modulation and binding. Such changes were absent for Ca~V~1.2:Ca~V~β~2a~ channels in which the Ca~V~β component is anchored to the membrane via palmitoylation.^[@ref74]^ The biophysical parameter changes were also accompanied by a reduction of channels at the cell membrane as indicated by the changes in the *I*~max~ parameter. Notably, such changes could also be observed for Ca~V~1.2:Ca~V~β~2a~, although to a lesser extent than with Ca~V~1.2-Y437A:Ca~V~β~2a~ or Ca~V~1.2:Ca~V~β~3~, suggesting that the peptides may not only affect channels at the membrane but inhibit the formation or membrane incorporation of newly assembled channels or may influence channel destruction by the ERAD system.^[@ref30]^ Interestingly, the time constants measured for the *I*~max~ changes are close to the intrinsic dissociation rates reported for the AID--Ca~V~β interaction^[@ref44]^ and suggest that some of the competitive effects of the peptides may be governed by the intrinsic dissociation rates of Ca~V~β from the pore-forming subunit. Together, our data demonstrate that the AID:ABP interaction can be targeted effectively in a cellular context. Importantly, despite the high similarity in the residues that contribute to the AID:ABP interface and the corresponding similar interaction affinities for AID--Ca~V~β pairs,^[@ref45]^ our findings show that it is possible to achieve some degree of isoform selective specificity. This selectivity appears to originate in factors outside of the ABP--AID interface that contribute to the diverse functional effects of the different Ca~V~β isoforms, that likely affect how Ca~V~β engages the channel, and that are related to the Ca~V~β off rate. Thus, our studies with stapled AID peptides show that it is possible to antagonize a paradigmatic protein--protein interaction central to VGIC function, for Ca~V~ current regulation and achieve specificity between different Ca~V~β isoforms.

VGICs have well-established important roles in the generation of bioelectrical signals in excitable tissues such as brain, heart, and muscle^[@ref1]^ and also have an emerging set of "nonclassical" roles in insulin secretion,^[@ref83]^ cancer,^[@ref84]−[@ref86]^ and gene regulation.^[@ref87],[@ref88]^ Because of these diverse functions and a general lack of specific means for controlling channel function, there remains a need to develop new molecular tools that can be used to probe VGIC biology.^[@ref51],[@ref89],[@ref90]^ Due to the importance of protein--protein interactions between pore-forming and cytoplasmic VGIC subunits for the biogenesis and trafficking of many VGICs, further development of such VGIC protein--protein interaction antagonists may open new means to study the dynamics of channel complexes, the steps associated with channel assembly, and the roles of these processes in native setting excitable tissues such as muscles and neurons.

Materials and Methods {#sec4}
=====================

Molecular Biology {#sec4.1}
-----------------

Human Ca~V~1.2 (α~1~C77, GenBank Z34815), human Ca~V~1.2-Y437A, rat Ca~V~β~2a~ (GenBank NM_053851), Ca~V~β~3~ (GenBank NM_001101715), and Ca~V~α~2~δ-1 (GenBank NM_00182276) were used for two-electrode voltage clamp experiments in *Xenopus* oocytes. For constructing Ca~V~1.2-Y437A, the mutation in position 437 of Ca~V~1.2 was introduced by SOE-PCR (Splicing by Overlap-PCR). Briefly, the I--II loop cDNA sequence of Ca~V~1.2 was PCR amplified with overlapping mutagenesis primers in separate PCR reactions using pcDNA3.1-Ca~V~1.2 as template. The two separate PCR products were then used as templates for a final PCR reaction with flanking primers to connect the nucleotide sequences. This fragment was then *Hpa*I/*Ppu*MI digested and cloned into the respective sites of pcDNA3.1-Ca~V~1.2.

Protein Expression and Purification {#sec4.2}
-----------------------------------

Ca~V~β~2a~ expression and purification were done as previously described.^[@ref45]^ For complex formation with stapled peptides, 155 uM Ca~V~β~2a~ in buffer A (150 mM KCl, 1 mM TCEP, pH 7.4, 10 mM HEPES/KOH, pH 7.4) was mixed with an equal volume of peptide in buffer A, creating a molar ratio of protein/peptide of 1:1.2. Unbound peptide was removed using a Superdex200 HR10/30 gel filtration column run in buffer A. The Ca~V~β~2a~/peptide complex was concentrated (Amicon filter, MWCO 10 kDa) to 8 mg/mL as determined by absorbance.^[@ref91]^

Peptide Synthesis and Purification {#sec4.3}
----------------------------------

All the AID peptides were synthesized using an automated peptide synthesizer (0.1 mmol scale). Fmoc-solid phase peptide synthesis was employed on Chemmatrix Rinkamde resin (substitution level ∼0.5 mmol/g). Deprotection was performed with 20% 4-methylpiperidine in DMF, and coupling reactions were done in a mixture of Fmoc-amino acid (5 equiv), HCTU (4.95 equiv), and DIPEA (10 equiv) in DMF at 70 °C for 5 min. The peptide was cleaved from the resin by treatment with the cleavage cocktail (TFA/EDT/thioanisole = 95:2.5:2.5), and the crude product was obtained by cold ether precipitation after removal of TFA. The crude peptide was purified by reverse phase (RP)-HPLC C4 column and lyophilized.

Peptide Cross-Linking {#sec4.4}
---------------------

Peptide cross-linking was performed as described previously.^[@ref59]^ Briefly, a solution of cysteine containing peptide (0.1 mM) was incubated with TCEP (1.5 equiv) in NH~4~HCO~3~ buffer (100 mM, pH = 8.0) for 30 min. Then *m*,*m*′-dibromoxylene solution (2 or 3 equiv, 1 mM in DMF) was added and stirred at room temperature. The reaction progress was monitored by mass spectrometry. When the reaction was complete, the reaction mixture was quenched by 1 M HCl solution to acidic pH (pH 3 or 4) and purified by RP-HPLC.

Crystallization and Refinement {#sec4.5}
------------------------------

The Ca~V~β~2a~/ASPL complex was crystallized by hanging drop vapor diffusion at 4 °C by mixing equal volumes of protein in buffer A and well solution containing 1.5--1.7 M (NH~4~)~2~SO~4~, 5 mM β-mercaptoethanol, and 0.1 M HEPES, pH 7. The Ca~V~β~2a~/CSPE complex was crystallized by hanging drop vapor diffusion at 4 °C by mixing equal volumes of protein in buffer A and well solution containing 34--37% PEG400, 0.1 M MgCl~2~, and 0.1 M MES, pH 6.3. After flash-freezing in well solution plus 20% glycerol, diffraction data were collected at Beamline 8.3.1 (Advanced Light Source, Lawrence Berkeley National Laboratories), indexed using MOSFLM 7.0.4,^[@ref92]^ and scaled using SCALA.^[@ref93]^ Molecular replacement with PHASER^[@ref94]^ using a model derived from 1T3S yielded starting phases. The initial model was improved by iterative cycles of manual building in COOT^[@ref95]^ and refinement against native data using Refmac5.^[@ref96]^ TLS-tensors were added in the final cycle of refinement. Data collection and final model refinement statistics are summarized in [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf).

Circular Dichroism {#sec4.6}
------------------

Circular dichroism spectra were measured in a 2 mm path length quartz cuvette (Hellma), 50 mM KCl, and 10 mM KH~2~PO~4~/K~2~HPO~4~, pH 7.3, using an Aviv model 215 spectropolarimeter (Aviv Biomedical) equipped with a Peltier temperature controller. Wavelength scans from 320 to 190 nm were taken at 4 °C. Each point was determined in triplicate from the same sample and subtracted by the average of a triplicate buffer scan. Each sample was checked for purity by HPLC. Molar ellipticity was calculated as follows: θ = 100(Δ*m*)/(*Cnl*), where Δ*m* is the CD signal in millidegrees after buffer subtraction, *C* is the millimolar peptide concentration, *n* is the number of residues in the peptide, and *l* is the cuvette path length in centimeters.

Isothermal Calorimetry {#sec4.7}
----------------------

Titrations were performed at 15 °C using a VP-ITC microcalorimeter (MicroCal). Samples were dialyzed overnight at 4 °C (Slide-A-Lyzer, 2 kDa molecular weight cutoff, Thermo Scientific) against 150 mM KCl and 10 mM potassium phosphate, pH 7.3. After 30 min centrifugation at 40 000 rpm at 4 °C, protein concentrations were determined by absorbance at 280 nm.^[@ref91]^ All samples were degassed for 5 min prior to loading into the calorimeter. Ca~V~1.2 Ca~V~β~2a~ core at a concentration of 2 μM was titrated with 20 μM modified or unmodified AID peptide with one 4 μL injection followed by 29 injections of 10 μL of titrant. To correct the baseline, heat of dilution from titrations of injectant into buffer was subtracted. Data were processed with MicroCal Origin 7.0 using a single site binding model.

Electrophysiology {#sec4.8}
-----------------

Details of two-electrode voltage clamp have been described previously.^[@ref64]^ In short, linearized cDNA was translated into capped mRNA using the T7 mMessenger kit (Ambion). Fifty nanoliters of a mRNA mixture containing an equimolar ratio of Ca~V~α~1~ and Ca~V~α~2~δ-1 and a lower amount of Ca~V~β were microinjected into *Xenopus* oocytes 48--72 h prior to recording. After injection, the oocytes were kept at 18 °C in ND96 medium supplemented with penicillin (100 U mL^--1^) and streptomycin (100 μg mL^--1^). Prior studies established that with injections of an equimolar ratio of Ca~V~α~1~ and Ca~V~β RNA, there is an excess of free Ca~V~β.^[@ref64]^ To avoid an excess of free Ca~V~β in the cytoplasm, the optimal Ca~V~α~1~/Ca~V~β RNA ratio was determined for each RNA preparation. Different Ca~V~α~1~/Ca~V~β molar ratios were titrated for every RNA preparation, and the highest Ca~V~α~1~/Ca~V~β RNA ratio at which the channel currents displayed the same extent and speed of inactivation as oocytes injected with equimolar ratio of Ca~V~α~1~/Ca~V~β was used for peptide injection experiments (1:10 to 1:100 for Ca~V~β~2a~:Ca~V~1.2; 1:1 for Ca~V~β~3~:Ca~V~1.2).

For experiments that involved peptide injections into oocytes, 5 min before the first recording, 50 nL of a mixture of 0.1 M BAPTA and the test substance (peptide or water) was injected. Recording solutions contained 40 mM Ca(NO~3~)~2~, 50 mM NaOH, 1 mM KOH, and 10 mM HEPES, adjusted to pH 7.4 using HNO~3~. Electrodes were filled with 3 M KCl and had resistances of 0.3--2.0 MΩ. Leak currents were subtracted using a P/4 protocol. Currents were analyzed with Clampfit 8.2 (Axon Instruments). All results are from at least two independent oocyte batches. The *t*~i300~ values were calculated from normalized currents at +20 mV and represent the percentage of inactivation after 300 ms. Inactivation τ values at +20 mV, *G*~max~, *K*~a~, *V*~1/2~, and *V*~rev~ were calculated as described.^[@ref64]^

Statistical Analysis {#sec4.9}
--------------------

Data are expressed as mean ± SEM. Statistical differences between samples were determined using one-way analysis of variance or Kruskal--Wallis one way analysis of variance on ranks (when data were not normally distributed) and two-way analysis of variance associated with a Holm--Sidak post hoc test when needed. A value of *p* \< 0.05 was considered significant.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acschemneuro.6b00454](http://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00454).Structures of Ca~V~β~2a~:stapled peptide complexes and crystallographic data ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acschemneuro.6b00454/suppl_file/cn6b00454_si_001.pdf))
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Coordinates and structure factors for have been deposited for Ca~V~β~2a~:Ca~V~1.2 AID-CAP (5V2P) and Ca~V~β~2a~:AID-CEN (5V2Q) and will be immediately available upon publication.
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